Kolexia
Gruel Yves
Médecine générale
Centre hospitalier de Tours
Tours, France
107 Activités
272 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Hémophilie A Hémorragie Urgences Afibrinogénémie Thromboembolie Thrombopénie Thromboembolisme veineux Thrombose Maladies foetales

Industries

KEPHREN PUBLISHING
46 collaboration(s)
Dernière en 2023
Octapharma
13 collaboration(s)
Dernière en 2022
Aguettant
8 collaboration(s)
Dernière en 2023
BMS
6 collaboration(s)
Dernière en 2022

Dernières activités

How to translate and implement the current science of gene therapy into haemophilia care?
Therapeutic advances in hematology   12 janvier 2023
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory.
Thrombosis journal   07 septembre 2020
Thrombotic risk in children undergoing orthopedic surgery.
Orthopaedics & traumatology, surgery & research : OTSR   16 décembre 2019
Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR).
Anaesthesia, critical care & pain medicine   23 octobre 2018
Analysis of big data for heparin-induced thrombocytopenia: valuable information but also some doubts.
The Lancet. Haematology   17 octobre 2018
Risk factors for thromboembolic disease in young women-the role of hormones.
Revue des maladies respiratoires   11 octobre 2018
CREHA: Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Essai Clinique (CHU Rouen)   25 mai 2018
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.
European journal of neurology   09 mars 2018
Postauthorization safety study of Clottafact , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.
Vox sanguinis   13 décembre 2017
Immunogenicity, efficacy and safety of Nuwiq (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.
Haemophilia : the official journal of the World Federation of Hemophilia   16 août 2017